The aim of the present study was to examine the potential of microRNAs as clinical markers and to elucidate the participation of the mir-200–ZEB–E-cadherin pathway in the progression of human cancers by using patient materials from metastatic colorectal and breast cancer. This evidence concerns the gene CDH1 and breast cancer.